Trial reportJournal of neurology, neurosurgery, and psychiatry1997
Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.
Trial report in Journal of neurology, neurosurgery, and psychiatry, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2021Pooled it
- Pooled it
- Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.AJNR. American journal of neuroradiology · 2003Trial
- Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.AJNR. American journal of neuroradiology · 2003Trial
- Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.European radiology · 2024Review
- Review
- Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis.Human brain mapping · 2019Article
- Conversion from radiologically isolated syndrome to multiple sclerosis.International journal of preventive medicine · 2014Article
- Perfusion and Diffusion Abnormalities of Multiple Sclerosis Lesions and Relevance of Classified Lesions to Disease Status.Journal of neurology & neurophysiology · 2014Article
- The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis.La Radiologia medica · 2007Article
- Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2006Article
- Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.Journal of neurology · 2004Review
- Enhancing patterns in multiple sclerosis: evolution and persistence.AJNR. American journal of neuroradiology · 2001Article
- Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.AJNR. American journal of neuroradiology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to evaluate the predictive power of baseline gadolinium (Gd) enhanced MRI in relation to subsequent clinical and MRI activity. Sixty eight patients with clinically definite relapsing-remitting multiple sclerosis had a baseline Gd enhanced MRI and were followed up clinically and by monthly Gd enhanced MRI for six months. The occurrence of relapses during the follow up period was predicted by the presence of at least one enhancing lesion on the baseline MRI (P < 0.05). The number and volume of enhancing lesions at baseline were significantly associated with both enhancing lesions observed during the follow up period (P < 0.0001) and the accumulation of abnormality on T2 weighted images (P < 0.0001). Moreover, the presence of three or more enhancing lesions at baseline scan was consistently associated with the development of permanent abnormalities on T2 weighted images six months later. The study suggests that the number and volume of Gd enhancing lesions at a single examination are strong short term predictors of subsequent clinical and MRI activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.